Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1(19)

Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1(19)

Author Rocha, Mariana Vilela Google Scholar
Francoso, Katia Sanches Google Scholar
Lima, Luciana Chagas Google Scholar
Camargo, Tarsila Mendes Google Scholar
Machado, Ricardo L. D. Google Scholar
Costa, Fabio T. M. Google Scholar
Renia, Laurent Google Scholar
Nosten, Francois Google Scholar
Russell, Bruce Google Scholar
Rodrigues, Mauricio M. Autor UNIFESP Google Scholar
Soares, Irene S. Google Scholar
Abstract Plasmodium vivax is the most widely distributed malaria species and the most prevalent species of malaria in America and Asia. Vaccine development against P. vivax is considered a priority in the global program for the eradication of malaria. Earlier studies have characterized the Apical Membrane Antigen 1 (AMA-1) ectodomain and the C-terminal region (19 kDa) of the Merozoite Surface Protein 1 (MSP-1) of P. vivax as immunodominant antigens. Based on this characterization, we designed a chimeric recombinant protein containing both merozoite immunodominant domains (PvAMA1(66)-MSP1(19)). The recombinant PvAMA166-MSP119 was successfully expressed in Pichia pastoris and used to immunize two different mouse strains (BALB/c and C57BL/6) in the presence of the Poly (I:C) as an adjuvant. Immunization with the chimeric protein induced high antibody titers against both proteins in both strains of mice as detected by ELISA. Antisera also recognized the native proteins expressed on the merozoites of mature P. vivax schizonts. Moreover, this antigen was able to induce IFN-gamma-secreting cells in C57BL/6 mice. These findings indicate that this novel yeast recombinant protein containing PvAMA1(66) and PvMSP1(19) is advantageous, because of improved antibody titers and cellular immune response. Therefore, this formulation should be further developed for pre-clinical trials in non-human primates as a potential candidate for a P. vivax vaccine. (C) 2017 Elsevier Ltd. All rights reserved.
Keywords Malaria
Plasmodium vivax
Recombinant vaccine
xmlui.dri2xhtml.METS-1.0.item-coverage Oxford
Language English
Sponsor Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
Instituto Nacional de Ciencia e Tecnologia de Vacinas (INCTV)
Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)
FAPESP
CNPq
CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)
Grant number CNPq: 475500/2012-1
FAPESP: 012/13032-5
FAPESP: 2011/23278-9
FAPESP: 2013/01487-0
Date 2017
Published in Vaccine. Oxford, v. 35, n. 18, p. 2463-2472, 2017.
ISSN 0264-410X (Sherpa/Romeo, impact factor)
Publisher Elsevier Sci Ltd
Extent 2463-2472
Origin http://dx.doi.org/10.1016/j.vaccine.2017.03.023
Access rights Closed access
Type Article
Web of Science ID WOS:000400715600028
URI https://repositorio.unifesp.br/handle/11600/54709

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account